Advertisement
INCY vs VRTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and VRTX is a StrongBuy.
INCY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for INCY turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 26 of 35 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, 23 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 63 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 207 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
INCY moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for INCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.732) is normal, around the industry mean (3.070). P/E Ratio (14.367) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Momentum Indicator for VRTX turns positive, indicating new upward trend
VRTX saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 64 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VRTX's RSI Oscillator exited the oversold zone, 10 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for VRTX just turned positive on October 20, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in 35 of 60 cases over the following month. The odds of a continued upward trend are 58%.
VRTX moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 236 of 369 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
VRTX broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.760) is normal, around the industry mean (3.070). P/E Ratio (31.196) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (439.237).
INCY | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 33 | 15 | |
SMR RATING 1..100 | 33 | 41 | |
PRICE GROWTH RATING 1..100 | 48 | 23 | |
P/E GROWTH RATING 1..100 | 50 | 35 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRTX's Valuation (91) in the Biotechnology industry is in the same range as INCY (92). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
VRTX's Profit vs Risk Rating (15) in the Biotechnology industry is in the same range as INCY (33). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is in the same range as VRTX (41). This means that INCY’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Price Growth Rating (23) in the Biotechnology industry is in the same range as INCY (48). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
VRTX's P/E Growth Rating (35) in the Biotechnology industry is in the same range as INCY (50). This means that VRTX’s stock grew similarly to INCY’s over the last 12 months.
| INCY | VRTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 62% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 58% |
| TrendWeek ODDS (%) | 2 days ago 59% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 68% |
| Advances ODDS (%) | 3 days ago 63% | 2 days ago 64% |
| Declines ODDS (%) | 5 days ago 55% | 5 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 48% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 46% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 2 FA rating(s) are green while VRTX’s FA Score has 2 green FA rating(s).
- INCY’s FA Score: 2 green, 3 red.
- VRTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 5 bearish.
- VRTX’s TA Score: 5 bullish, 5 bearish.
Price Growth
INCY (@Biotechnology) experienced а -0.11% price change this week, while VRTX (@Biotechnology) price change was +0.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.39%. For the same industry, the average monthly price growth was -11.11%, and the average quarterly price growth was -14.21%.
Reported Earning Dates
INCY is expected to report earnings on Feb 09, 2027.
VRTX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (+5.39% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement